Dataset Information

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

ABSTRACT:

Purpose

Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeutic options. This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer.

Patients and methods

Patients with thyroid cancer of any histology that was resistant or not appropriate for (131)I were enrolled onto a single-arm phase II trial to receive axitinib orally (starting dose, 5 mg twice daily). Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors was the primary end point. Secondary end points included duration of response, progression-free survival (PFS), overall survival, safety, and modulation of soluble (s) VEGFR.

Results

Sixty patients were enrolled. Partial responses were observed in 18 patients, yielding an ORR of 30% (95% CI, 18.9 to 43.2). Stable disease lasting > or = 16 weeks was reported in another 23 patients (38%).

Objective

responses were noted in all histologic subtypes. Median PFS was 18.1 months (95% CI, 12.1 to not estimable). Axitinib was generally well tolerated, with the most common grade > or = 3 treatment-related adverse event being hypertension (n = 7; 12%). Eight patients (13%) discontinued treatment because of adverse events. Axitinib selectively decreased sVEGFR-2 and sVEGFR-3 plasma concentrations versus sKIT, demonstrating its targeting of VEGFR.

Conclusion

Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.

SUBMITTER: Cohen EE

PROVIDER: S-EPMC4859206 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Abstract Background: vascular endothelial growth factor receptor (VEGFR) signal transduction mediates glioblastoma (GB) associated neo-angiogenesis. The AXIG trial (NCT01562197) is a randomized clinical trial that initially investigated the activity of axitinib as a monotherapy (AXI-arm) versus physicians best alternative choice of therapy (Duerinck et al. JNO Mar 2016) and following amendment versus axitinib plus lomustine (Duerinck et al. ASCO AM 2016). Methods: an updated pooled analysis was made of the clinical outcome of all patients who initiated treatment with axitinib mono-therapy or axitinib in combination with lomustine in the AXIG trial. Results: between August 2011 and July 2015, a total of 78 pts were enrolled in the trial and initiated treatment with axitinib monotherapy (N: 50; AXI) or axitinib plus lomustine (N: 28; AXILOM). Median age was 55y [range 18–80], 50M/28F, 19, 29, 19, 7 and 4 pts had a WHO-PS of 0, 1, 2, 3 and 4 respectively. Baseline characteristics were well balanced between study arms (AXI vs AXILOM). All pts had failed prior surgery, RT and TMZ. Thirteen pts in the AXI-arm crossed-over at the time of progression (AXIseqLOM). Treatment was generally well tolerated. AXILOM pts were at higher risk for grade 3/4 adverse events (most frequent gr3/4 AE on AXILOM vs AXI were: thrombocytopenia 3- vs 0 pts, hypertension 2 vs 2 pts, anorexia 3 vs 3 pts). The best overall tumor response (by RANO criteria) was 2 CR/ 11 PR/ 11 SD/ 26 PD in the AXI arm (BORR 26%) vs. 1 CR/ 9 PR/ 3 SD/ 13 PD in the AXILOM-arm (BORR 38%). Adding CCNU to axitinib after progression (AXIseqLOM) resulted in 1 pt experiencing PR and 8pts experiencing SD. Six-mths PFS and OS rates were respectively 26% (95% CI 14–38) vs 17% (95% CI 2–32), and 54% (95% CI 40–68) vs. 53% (95% CI 34–73) for pts treated in the AXI vs. AXILOM-arms; median PFS and OS were respectively 12 vs. 16 wks and 25 vs. 27 wks. When the time-to-second progression was taken into account for the 9 AXIseqLOM patients who experienced PR or SD following the addition of lomustine at first PD on axitinib, 6-mths PFS was 39% (95% CI 21–57). No significant correlation was found between clinical outcome measures and the MGMT promoter methylation status or IDH1/2 mutation status. Conclusion: Axitinib has single-agent activity in patients with recurrent GB; upfront combination of axitinib and LOM did not significantly increase progression-free or overall survival in patients with recurrent glioblastoma. Adding CCNU to axitinib after progression seems to result in improved PFS compared to upfront combination therapy.

Project description:IntroductionCombining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1 antibody with clinical activity in various tumor types; axitinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. We report the final analysis from VEGF Liver 100 (NCT03289533), a phase 1b study evaluating safety and efficacy of avelumab plus axitinib in treatment-naive patients with aHCC.MethodsEligible patients had confirmed aHCC, no prior systemic therapy, ≥1 measurable lesion, Eastern Cooperative Oncology Group performance status ≤1, and Child-Pugh class A disease. Patients received avelumab 10 mg/kg intravenously every 2 weeks plus axitinib 5 mg orally twice daily until progression, unacceptable toxicity, or withdrawal. Endpoints included safety and investigator-assessed objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) for HCC.ResultsTwenty-two Japanese patients were enrolled and treated with avelumab plus axitinib. The minimum follow-up was 18 months as of October 25, 2019 (data cutoff). Grade 3 treatment-related adverse events (TRAEs) occurred in 16 patients (72.7%); the most common (≥3 patients) were hypertension (n = 11 [50.0%]), palmar-plantar erythrodysesthesia syndrome (n = 5 [22.7%]), and decreased appetite (n = 3 [13.6%]). No grade 4 TRAEs or treatment-related deaths occurred. Ten patients (45.5%) had an immune-related AE (irAE) of any grade; 3 patients (13.6%) had an infusion-related reaction (IRR) of any grade, and no grade ≥3 irAE and IRR were observed. The objective response rate was 13.6% (95% CI: 2.9-34.9%) per RECIST 1.1 and 31.8% (95% CI: 13.9-54.9%) per mRECIST for HCC.ConclusionTreatment with avelumab plus axitinib was associated with a manageable toxicity profile and showed antitumor activity in patients with aHCC.